Jan 09, 2024 / 09:30PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it is my pleasure to be hosting this fireside chat with the Organon management today. From the company, we have CEO, Kevin Ali; as well as CFO, Matt Walsh. Kevin and Matt. Happy New Year. Thanks for joining us again today.
I thought, Kevin, maybe just to kick off, it would be interested in just maybe some bigger picture thoughts on the business heading into 2024, and then we'll dive into the specifics of the business from there.
Kevin Ali - Organon & Co. - CEO & Director
Sure. Well, I think, Chris, and thanks for the introduction and for hosting this. I think you saw an -- actually, just yesterday, we had an announcement that we made at JPM, a press release where we essentially did a few things. One is we reaffirmed our guidance for 2023. And also, we said that our cash position is probably going to be a little bit better on the high side in terms of our range for '23. And then we kind of gave a
Organon & Co at JPMorgan Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers